This study was designed to evaluate the role of PIVKA-II as a diagnostic marker of HCC by comparing serum levels of PIVKA-II and alpha-fetoprotein (AFP) in HCC patients and in two control groups, patients with chronic liver disease and cirrhosis without HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.